1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,089 | 0,112 | 12:34 | |
| 0,090 | 0,110 | 12:20 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | BRII-B (02137): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | - | HKEx | ||
| 17.09. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 17.09. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 17.09. | BRII-B (02137): 2026 INTERIM REPORT | 1 | HKEx | ||
| 16.09. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.08. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 21.08. | Brii Biosciences H1 Loss Narrows, Stock Up | 2 | RTTNews | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 21.08. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results | 266 | PR Newswire | Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395... ► Artikel lesen | |
| 21.08. | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 07.08. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | Brii Bio reports mixed results from hepatitis B studies | 3 | Investing.com | ||
| 03.07. | Brii Biosciences Limited: Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | 172 | PR Newswire | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses... ► Artikel lesen | |
| 03.07. | BRII-B (02137): INSIDE INFORMATION ANNOUNCES TOPLINE END-OF-TREATMENT DATA FROM PHASE 2B ENRICH AND ENHANCE STUDIES FOR THE TREATMENT OF CHRONIC HEPATITIS ... | 1 | HKEx | ||
| 17.06. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT SHARE BUY-BACK PROGRAMME | - | HKEx | ||
| 16.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2026 | - | HKEx | ||
| 22.05. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 3 | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 23.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 195,54 | +0,41 % | Kampf um den 40-Milliarden-US-Dollar-Alzheimer-Markt: So positionieren sich Eli Lilly, Biogen, Roche, Otsuka und NeuroThera | ||
| ILLUMINA | 237,30 | +0,61 % | Biotech Stocks At 52-Week Highs - Vaxcyte +31% On Phase 3 Results, InfuSystem, Illumina +7%, Charles River Laboratories +7%, HeartFlow +5% | SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data.Vaxcyte Inc. (PCVX)Vaxcyte is... ► Artikel lesen | |
| NANOREPRO | 1,720 | -1,15 % | Original-Research: NanoRepro AG (von NuWays AG): KAUFEN | Original-Research: NanoRepro AG - von NuWays AG
05.10.2026 / 09:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| CYTODYN | 0,200 | 0,00 % | CytoDyn Inc.: CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026 | ||
| IMMUNIC | 6,802 | +1,07 % | EQS-News: Immunic AG: Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 23,010 | -1,07 % | Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure | SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune... ► Artikel lesen | |
| GENPREX | 2,750 | 0,00 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| PERSONALIS | 14,130 | -1,33 % | Personalis, Inc. - 8-K, Current Report | ||
| VITROLIFE | 8,270 | -0,84 % | Vitrolife AB: Vitrolife Group appoints Erin Schardt Senior Vice President and General Manager, Americas. She will join the Executive Management Team. | Vitrolife Group today announced the appointment of Erin Schardt as Senior Vice President and General Manager, Americas, effective immediately. In this expanded role, Erin will assume responsibility... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| LEGEND BIOTECH | 16,700 | 0,00 % | Legend Biotech Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | Enveric receives U.S. patent allowance for psychiatric compounds | ||
| ENANTA | 10,600 | -0,93 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus | MAVIRET (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 0,920 | -13,21 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces Fiscal 2026 Q4 and YTD Results | CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 72,30 | -3,34 % | Monopar Therapeutics Inc.: Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 | WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen |
Das Unternehmen BRII BIOSCIENCES LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,106 Euro und damit +10,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.